• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Exscientia Plc (Amendment)

    2/14/23 11:09:29 AM ET
    $EXAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $EXAI alert in real time by email
    SC 13G/A 1 brhc10048142_sc13ga.htm SC 13G/A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G
    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED
    PURSUANT TO RULE 13d-2
     (Amendment No. 1) *

    Exscientia plc
    (Name of Issuer)

    Ordinary Shares
    (Title of Class of Securities)

    30223G102
    (CUSIP Number)

    December 31, 2022
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP NO.  57777K106
    Page 2 of 5 Pages

    1
    NAMES OF REPORTING PERSONS
     
     
    Andrew Hopkins
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United Kingdom
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    18,626,300 shares
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    498,600 shares
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    18,626,300 shares
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    498,600 shares
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    19,124,900 shares
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    15.6%1
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     


    1 Based upon 122,878,479 Ordinary Shares of the Issuer outstanding as of September 30, 2022, as reported in the Issuer’s Form 6-K filed with the Securities and Exchange Commission (“SEC”) on November 15, 2022.


    CUSIP NO.  57777K106
    Page 3 of 5 Pages

    Item 1 (a). Name of Issuer: Exscientia plc

    Item 1 (b).
    Address of Issuer’s Principal Executive Offices:  The Schrödinger Building, Oxford Science Park, Oxford OX4 4GE, United Kingdom

    Item 2 (a).
    Name of Person Filing:  Andrew Hopkins (“Hopkins”)

    Item 2 (b).
    Address of Principal Business Office or, if none, Residence:  Copse House, 61B Oxford Road, Abingdon, Oxfordshire, OX14 2AA, United Kingdom

    Item 2 (c).
    Citizenship:  Hopkins is a British citizen.

    Item 2 (d).
    Title of Class of Securities:  Ordinary Shares

    Item 2 (e).
    CUSIP Number:  30223G102

    Item 3.
    If this Statement is filed pursuant to §§240.13d‑1(b) or 240.13d‑2(b) or (c), check whether the person filing is a:

     
    (a)
    ☐
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
           
     
    (b)
    ☐
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
           
     
    (c)
    ☐
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
           
     
    (d)
    ☐
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
           
     
    (e)
    ☐
    An investment adviser in accordance with §240.13d‑1(b)(1)(ii)(E);
           
     
    (f)
    ☐
    An employee benefit plan or endowment fund in accordance with §240.13d‑1(b)(1)(ii)(F);
           
     
    (g)
    ☐
    A parent holding company or control person in accordance with §240.13d‑1(b)(1)(ii)(G);
           
     
    (h)
    ☐
    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
     
    (i)
    ☐
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
     
    (j)
    ☐
    A non-U.S. institution, in accordance with §240.13d‑1(b)(1)(ii)(J);
           
     
    (k)
    ☐
    Group, in accordance with §240.13d‑1(b)(1)(ii)(K).

    If filing as a non-U.S. institution in accordance with §240.13d‑1(b)(1)(ii)(J), please specify the type of institution.

    Not applicable.


    CUSIP NO.  57777K106
    Page 4 of 5 Pages

    Item 4.
    Ownership


    (a)
    Amount beneficially owned:  See Row 9 of the cover page for the Reporting Person.  The Reporting Person disclaims beneficial ownership with respect to these shares except to the extent of such Reporting Person’s pecuniary interest therein.


    (b)
    Percent of class:  See Row 10 of the cover page for the Reporting Person.

     
    (c)
    Number of shares as to which such person has:

    Hopkins may be deemed the beneficial owner of 19,124,900 Ordinary Shares, which consists of 16,526,300 Ordinary Shares held by Hopkins, 2,100,000 Ordinary Shares held in trust by the Nia Hopkins Charitable Trust (the “Trust”) and 498,600 held by Iva Hopkins Navratilova, his spouse. Hopkins is the sole trustee of the Trust and retains sole voting power over such shares.


    (i)
    Sole power to vote or to direct the vote:  See Row 5 of the cover page for the Reporting Person.
     

    (ii)
    Shared power to vote or to direct the vote:  See Row 6 of the cover page for the Reporting Person.
     

    (iii)
    Sole power to dispose or to direct the disposition of:  See Row 7 of the cover page for the Reporting Person.
     

    (iv)
    Shared power to dispose or to direct the disposition of:  See Row 8 of the cover page for the Reporting Person.

    Item 5.
    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person
     
    Not applicable.

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person
     
    Not applicable.

    Item 8.
    Identification and Classification of Members of the Group
     
    Not applicable.

    Item 9.
    Notice of Dissolution of Group
     
    Not applicable.

    Item 10.
    Certifications.
     
    Not Applicable.
     

    CUSIP NO.  57777K106
    Page 5 of 5 Pages

    SIGNATURE

    After reasonable inquiry and to the best of the undersigned’s knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: February 14, 2023
       
         
     
    /s/ Andrew Hopkins
     
     
    Name:
    Andrew Hopkins



    Get the next $EXAI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EXAI

    DatePrice TargetRatingAnalyst
    7/9/2024Buy
    TD Cowen
    1/5/2024$11.00 → $9.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $EXAI
    Financials

    Live finance-specific insights

    See more
    • Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout

      Maximises upside potential of precision-designed GTAEXS617 with purchase of rights from GT Apeiron Monotherapy dose escalation data readout for ELUCIDATE Phase 1/2 trial on track for second half of 2024 Combination dose escalation study starting with HR+/HER2- breast cancer to commence in late 2024/early 2025 Exscientia plc (NASDAQ:EXAI) today announced it has reached an agreement to acquire GT Apeiron's share of its oral CDK7 inhibitor programme, gaining full control of GTAEXS617 (‘617) and all related intellectual property. The monotherapy dose escalation phase of ELUCIDATE is designed to assess the safety, pharmacokinetics and pharmacodynamics of '617 in advanced solid tumours. R

      7/18/24 7:00:00 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exscientia Business Update for First Quarter 2024

      Positive early Phase 1 results for BMS-partnered programme ‘4318 (PKC-theta inhibitor) GTAEXS617 (CDK7 inhibitor) initial Phase I data expected in 2H24 LSD1 and MALT1 inhibitor programmes expected to advance into clinic in 2H24 and early 2025, respectively AI-design integration enhanced with full experiment automation driving towards maximum speed, quality and autonomous drug design Leveraging technology advancements and streamlining operations to realise annualised savings of $40 million Exscientia plc (NASDAQ:EXAI): Recent advancements in the Company's pipeline, collaborations and operations, as well as financial results for the first quarter 2024, are summarised below. Exscient

      5/21/24 7:00:00 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exscientia to Report First Quarter 2024 Financial Results on May 21, 2024

      Company to host conference call and webcast on May 21, 2024, at 1:30 p.m. BST / 8:30 a.m. EDT Exscientia plc (NASDAQ:EXAI) will report financial results for the first quarter ended March 31, 2024, on Tuesday, May 21, 2024, before the open of U.S. markets. The Company will host a conference call and webcast at 1:30 p.m. BST / 8:30 a.m. EDT to provide a business update and review financial results. A webcast of the live call can be accessed by visiting the "Investors and Media" section of the Company's website at investors.exscientia.ai. Alternatively, the live conference call can be accessed by dialing +1 (888) 330 3292 (U.S.), +44 (800) 358 0970 (U.K.), +1 (646) 960 0857 (International)

      5/14/24 7:00:00 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXAI
    Leadership Updates

    Live Leadership Updates

    See more
    • Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

      Brings together Recursion's scaled biology exploration and translational capabilities with Exscientia's precision chemistry design and small molecule automated synthesis capabilities to create a leading technology-first, end-to-end drug discovery platformCombined business positioned to leverage latest advances in the life sciences and technology to deliver better novel treatments to patients, faster and at a lower cost relative to traditional drug discovery and development methodsHighly complementary pipeline with approximately 10 clinical readouts expected over the next 18 monthsIndustry-leading portfolio of pharma partnerships with the potential for approximately $200 million in milestone

      8/8/24 7:39:25 AM ET
      $EXAI
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

      — AI drug design pioneer John P. Overington, Ph.D., appointed to Chief Technology Officer to maximise strategic technology integration and application — — Maria-Louise Fjällskog, M.D., Ph.D., appointed interim Chief Medical Officer, adding extensive oncology drug development expertise to execute robust clinical strategy on Exscientia's internal oncology pipeline — Exscientia plc (NASDAQ:EXAI) today announced the appointment of two technology and clinical development leaders to senior roles to significantly strengthen the impact of differentiating technology applications as well as focused oncology pipeline development. Appointed to Chief Technology Officer, John P. Overington, Ph.D.,

      6/6/24 7:00:00 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Parker Moss to Join Exscientia as EVP, Corporate Development

      Renowned technology champion to strengthen company's development of precision medicine and clinical innovation platforms Exscientia plc (NASDAQ:EXAI) today announced the appointment of Parker Moss as Executive Vice President, Corporate Development, effective January, 2024. In this newly established role, Parker will lead the creation and execution of a focused corporate development strategy to strengthen further and create new market opportunities for the company's precision medicine, clinical and tech innovation platforms, with a particular focus on oncology. Reporting to CEO Andrew Hopkins, he will help the company's Executive Leadership Team to identify and shape new business opportuni

      10/17/23 7:00:00 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXAI
    SEC Filings

    See more
    • SEC Form 15-12G filed by Exscientia Plc

      15-12G - Exscientia plc (0001865408) (Filer)

      12/2/24 8:39:14 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Exscientia Plc

      S-8 POS - Exscientia plc (0001865408) (Filer)

      11/20/24 10:01:22 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Exscientia Plc

      S-8 POS - Exscientia plc (0001865408) (Filer)

      11/20/24 9:53:01 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXAI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

      Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will focus on first and best-in-class drug discovery and development, demonstrating the ability to find novel insights and dramatically reduce the time and cost of discoveryRecursion will host an update call today, November 20, 2024 at 7:30 a.m. ET / 5:30 a.m. MT / 12:30 p.m. GMT on LinkedIn, X and Youtube SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (NASDAQ:RXRX) and Exscientia has been completed, wi

      11/20/24 7:00:00 AM ET
      $EXAI
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion and Exscientia Shareholders Approve the Proposed Combination

      Salt Lake City USA, Oxford UK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX) and Exscientia plc (NASDAQ:EXAI) have each received overwhelming approval from their shareholders for the proposed combination between Recursion and Exscientia.  The transaction is expected to close on November 20, 2024, subject to the satisfaction or waiver of the remaining customary closing conditions. Recursion expects to host an update call after the anticipated close on November 20, 2024 at 7:30 a.m. ET /  5:30 a.m MT / 12:30 p.m. GMT. The company will broadcast the live stream from Recursion's X (formerly Twitter), LinkedIn and YouTube accounts. Questions can be submitted via this link ahead of

      11/13/24 9:08:19 AM ET
      $EXAI
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration

      Both programmes demonstrate Exscientia's ability to design highly differentiated, potentially best-in-class molecules Exscientia will receive $15 million for achieving these milestones and is eligible for over $600 million in additional milestone payments for these two programmes as well as high-single-digit to mid-teen royalties Three programmes in the partnership have now advanced through initial milestones with multiple more progressing at earlier stages Exscientia plc (NASDAQ:EXAI) today announced the advancement of two additional discovery programmes within its collaboration with Sanofi, with Exscientia receiving an aggregate of $15 million in milestone payments. Both lead compounds

      10/16/24 7:00:00 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Exscientia Plc

      SC 13G/A - Exscientia plc (0001865408) (Subject)

      11/22/24 9:11:55 PM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Exscientia Plc

      SC 13D/A - Exscientia plc (0001865408) (Subject)

      11/22/24 8:00:16 PM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Exscientia Plc (Amendment)

      SC 13G/A - Exscientia plc (0001865408) (Subject)

      2/12/24 11:05:40 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Exscientia plc

      TD Cowen initiated coverage of Exscientia plc with a rating of Buy

      7/9/24 7:31:11 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exscientia plc downgraded by BofA Securities with a new price target

      BofA Securities downgraded Exscientia plc from Buy to Neutral and set a new price target of $9.00 from $11.00 previously

      1/5/24 7:41:29 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care